IKT Stock Price, Chart, Stats & News
Inhibikase Therapeutics Inc (IKT) does not currently pay a dividend.
IKT chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -26.63% |
ROE | -46.90% |
D/E | – |
Interest coverage ratio | – |
IKT valuation
P/E | – |
P/S | – |
P/B | 0.96x |
P/CF | -5.94x |
P/FCF | -4.22x |
P/OCF | -5.94x |
PEG | -0.27x |
EV multiple | -4.97x |
About
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib.
Similar securities
Based on sector and market capitalization
